Group 1 - Collegium Pharmaceutical Inc. has entered into an agreement with Corium Therapeutics Holdings for the acquisition of AZSTARYS, involving $650 million in cash payments and potential earn-out considerations of up to $135 million [1][2] - The acquisition is expected to diversify the company's revenue streams beyond pain medicines and strengthen its position in the ADHD market, contributing to revenue through the late 2030s [2] - Collegium's existing operational and marketing capabilities in ADHD are anticipated to enhance margins and increase operating leverage following the acquisition [2] Group 2 - Collegium Pharmaceutical Inc. has been named an official partner of Boston Legacy FC, establishing a multi-year partnership aimed at improving fan experience during home games [3] - The partnership includes the creation of the Collegium Sensory Room at Gillette, Centreville, and White Stadium, designed to provide a peaceful environment for fans during matches [4] - This initiative aims to enhance the overall experience for visitors by offering a safer and more comfortable setting away from the intense match environment [4] Group 3 - Collegium Pharmaceutical Inc. specializes in the development and commercialization of pain management medicines, offering a diverse product range including Jornay PM, Belbuca, Xtampza ER, Nucynta ER, Nucynta IR, and Symproic [5]

Core Insights - Collegium Pharmaceutical reported revenue of $205.45 million for the quarter ended December 2025, reflecting a year-over-year increase of 12.9% [1] - The earnings per share (EPS) for the quarter was $2.04, up from $1.77 in the same quarter last year, but below the consensus estimate of $2.19, resulting in an EPS surprise of -6.99% [1] - The revenue fell short of the Zacks Consensus Estimate of $208.65 million, leading to a revenue surprise of -1.53% [1] Revenue Breakdown - Total product revenues for Belbuca reached $59.14 million, exceeding the three-analyst average estimate of $58.03 million, with a year-over-year change of +7.1% [4] - Xtampza ER generated $48.58 million in product revenues, which was below the average estimate of $51.37 million, showing a year-over-year decline of -5.6% [4] - Symproic reported revenues of $3.89 million, surpassing the average estimate of $3.53 million, but reflecting a year-over-year decrease of -8.6% [4] - Nucynta achieved $47.95 million in revenues, slightly below the average estimate of $49.47 million, with a year-over-year increase of +14.8% [4] - Jornay PM's revenues were $45.89 million, close to the average estimate of $46.46 million [4] Stock Performance - Collegium Pharmaceutical's shares have returned +2.1% over the past month, outperforming the Zacks S&P 500 composite, which changed by +0.6% [3] - The stock currently holds a Zacks Rank 3 (Hold), indicating expected performance in line with the broader market in the near term [3]

Core Thesis - Collegium Pharmaceutical, Inc. is viewed as an undervalued investment opportunity, particularly due to its stable cash-generating pain portfolio and growth potential in the ADHD segment [2][5]. Company Overview - As of September 24th, Collegium's shares were trading at $35.16, with trailing and forward P/E ratios of 32.92 and 4.87 respectively [1]. - The company has historically faced stigma due to its opioid focus but has successfully commercialized products like Xtampa ER, Belbuca®, Symproic, and Nucynta without heavy R&D spending [2]. Recent Developments - The acquisition of BioDelivery Sciences International in 2022 allowed Collegium to bring Belbuca fully in-house, enhancing its control over commercialization and revenue [3]. - Collegium has entered the ADHD market with Jornay PM, which has over 20% market share in its niche and a projected 5-year CAGR of 5-6% [3]. Management and Strategy - The new management team, led by Vikram Karnani and David Dieter, has a strong track record in scaling niche pharmaceuticals through capital-light acquisitions and disciplined capital allocation [4]. - Collegium's pain portfolio funds growth in ADHD while maintaining exclusivity on key products until the early 2030s, creating high barriers to competition [4]. Financial Metrics - The company is trading at under 5x EV/EBITDA with steady double-digit ROIC, indicating it is undervalued compared to peers [5]. - There is a reasonable upside potential to $60 per share, with a bull scenario projecting $120 [5]. Market Position - Collegium is positioned as an overlooked specialty pharma opportunity with significant risk-adjusted upside, driven by a combination of stable cash flow and growth initiatives [5].

Core Insights - Collegium Pharmaceutical reported $188 million in revenue for the quarter ended June 2025, marking a year-over-year increase of 29.4% and an EPS of $1.68 compared to $1.62 a year ago [1] - The revenue exceeded the Zacks Consensus Estimate of $180.38 million by 4.23%, and the EPS also surpassed the consensus estimate of $1.62 by 3.7% [1] Revenue Breakdown - Total product revenues for Belbuca were $52.6 million, slightly below the average estimate of $54.94 million, reflecting a year-over-year change of +0.8% [4] - Xtampza ER generated $52.61 million, exceeding the average estimate of $48.28 million, with an 18% increase compared to the previous year [4] - Jornay PM reported revenues of $32.63 million, slightly above the average estimate of $32.23 million [4] - Nucynta achieved $46.45 million in revenues, surpassing the average estimate of $43.31 million, representing a year-over-year change of +4.4% [4] - Symproic revenues were $3.72 million, exceeding the average estimate of $3.45 million, but showing a decline of 7.7% year-over-year [4] Stock Performance - Collegium Pharmaceutical's shares have returned -8.1% over the past month, contrasting with the Zacks S&P 500 composite's +1.2% change [3] - The stock currently holds a Zacks Rank 3 (Hold), indicating potential performance in line with the broader market in the near term [3]

Core Insights - Collegium Pharmaceutical reported $177.76 million in revenue for Q1 2025, a year-over-year increase of 22.7% [1] - The EPS for the same period was $1.49, compared to $1.45 a year ago, indicating a positive trend [1] - The revenue exceeded the Zacks Consensus Estimate of $172.45 million by 3.08%, and the EPS also surpassed the consensus estimate of $1.43 by 4.20% [1] Revenue Breakdown - Total product revenues for Belbuca were $51.66 million, slightly below the estimated $53.86 million, reflecting a 2% year-over-year increase [4] - Xtampza ER generated $47.64 million, exceeding the average estimate of $46.49 million, with a year-over-year change of 4% [4] - Jornay PM reported revenues of $28.54 million, closely matching the average estimate of $28.50 million [4] - Nucynta achieved $47.10 million in revenues, surpassing the average estimate of $42.13 million, marking a 4.3% year-over-year increase [4] - Symproic's revenues were $2.82 million, falling short of the average estimate of $3.25 million, representing a year-over-year decline of 14.7% [4] Stock Performance - Collegium Pharmaceutical's shares returned +2.6% over the past month, while the Zacks S&P 500 composite increased by +11.3% [3] - The stock currently holds a Zacks Rank 3 (Hold), suggesting it may perform in line with the broader market in the near term [3]